Erratum: Future therapies in melasma: What lies ahead?
How to cite this article:
. Erratum: Future therapies in melasma: What lies ahead?.Indian J Dermatol Venereol Leprol 2020;86:608-608
How to cite this URL:
. Erratum: Future therapies in melasma: What lies ahead?. Indian J Dermatol Venereol Leprol [serial online] 2020 [cited 2020 Nov 27 ];86:608-608
Available from: https://www.ijdvl.com/text.asp?2020/86/5/608/292501
In the article titled “Future therapies in melasma: What lies ahead?”, published in pages 8-17, issue 1, vol. 86 of Indian Journal of Dermatology, Venereology and Leprology, there are figure citations and legend mismatches:
Fig 2: Legend -Drugs targeting hyperactive melanocytes, to be cited after 'Newer agents targeting hyperactive melanocytes' (Pg.9); (Current Fig. 2 citation- to be removed) Fig 4- Legend 'Drugs targeting melanosome transfer to keratinocytes. To be cited after the subheading: 'Newer agents targeting melanosomal transfer' (Pg.11) [Figure 5]: Legend 'Role of a defective skin barrier in melasma'; [Figure 4] cited currently on page 11 to be cited as [figure 5]. (Current Fig 5 citation – to be removed) [Figure 6]: Legend 'Role of Endocrine factors in melasma'. [Figure 6] to be cited on page 12 after 'Newer agents targeting hormones' (Current fig 6 citation in the conclusion – to be removed)
Sarkar R, Bansal A, Ailawadi P. Future therapies in melasma: What lies ahead? Indian J Dermatol Venereol Leprol 2020;86:8-17.